Invesco
STRO icon

Invesco’s Sutro Biopharma STRO Stock Holding History

Invesco’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.9M Buy
57,305
+40,140
+234% +$1.25M ﹤0.01% 2609
2026
Q1 		$428K Buy
17,165
+195
+1% +$3.52K ﹤0.01% 3220
2025
Q4 		$196K Buy
16,970
+3,478
+26% +$33K ﹤0.01% 3535
2025
Q3 		$117K Buy
13,492
+3,160
+31% +$26.9K ﹤0.01% 3662
2025
Q2 		$73.8K Buy
10,332
+1,118
+12% +$9.14K ﹤0.01% 3689
2025
Q1 		$59.9K Buy
9,214
+5,339
+138% +$84.1K ﹤0.01% 3683
2024
Q4 		$71.3K Buy
3,875
+1,362
+54% +$41.6K ﹤0.01% 3663
2024
Q3 		$86.9K Sell
2,513
-113
-4% -$4.43K ﹤0.01% 3635
2024
Q2 		$76.9K Buy
2,626
+6
+0.2% +$237 ﹤0.01% 3780
2024
Q1 		$148K Sell
2,620
-442
-14% -$19.5K ﹤0.01% 3698
2023
Q4 		$131K Buy
3,062
+923
+43% +$29.3K ﹤0.01% 3649
2023
Q3 		$74.2K Sell
2,139
-39
-2% -$1.7K ﹤0.01% 3762
2023
Q2 		$101K Buy
2,178
+234
+12% +$11.6K ﹤0.01% 3726
2023
Q1 		$89.8K Sell
1,944
-4,330
-69% -$275K ﹤0.01% 3713
2022
Q4 		$507K Buy
6,274
+344
+6% +$23.9K ﹤0.01% 3256
2022
Q3 		$329K Sell
5,930
-202
-3% -$12K ﹤0.01% 3471
2022
Q2 		$320K Buy
6,132
+719
+13% +$40.2K ﹤0.01% 3543
2022
Q1 		$445K Sell
5,413
-11,209
-67% -$1.07M ﹤0.01% 3454
2021
Q4 		$2.47M Sell
16,622
-17,902
-52% -$3.21M ﹤0.01% 2719
2021
Q3 		$6.52M Buy
34,524
+895
+3% +$170K ﹤0.01% 2250
2021
Q2 		$6.25M Buy
33,629
+4,326
+15% +$847K ﹤0.01% 2330
2021
Q1 		$6.67M Buy
29,303
+22,584
+336% +$5.36M ﹤0.01% 2214
2020
Q4 		$1.46M Buy
+6,719
New +$1.11M ﹤0.01% 2771

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Invesco's STRO Position: Q2 2026 in Review

Invesco increased its Sutro Biopharma (STRO) stake by 234% in Q2 2026, buying an estimated $1.25M and bringing the position to 57,305 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2609.

Invesco first reported a position in STRO in Q4 2020 and has held it in 23 quarters since. The position peaked at $6.67M in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Invesco held 57,305 shares of Sutro Biopharma worth $1.9M as of Q2 2026.
  • Invesco bought 40,140 Sutro Biopharma shares in Q2 2026, an estimated $1.25M.
  • Sutro Biopharma made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2609 holding.
  • Invesco first reported a position in Sutro Biopharma in Q4 2020 and has held it in 23 quarters since.
  • Invesco's Sutro Biopharma position peaked at $6.67M in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.